New cancer pill tested in humans for first time
NCT ID NCT05478486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to see if the drug is safe enough for further study.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) of TATA Memorial Centre
Navi Mumbai, Maharashtra, 410210, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a new tracer light up hidden prostate cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Can your own immune cells beat advanced cancer?